Antonella Messina

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10193997/publications.pdf

Version: 2024-02-01

56 papers	3,199 citations	201674 27 h-index	175258 52 g-index
59 all docs	59 docs citations	59 times ranked	3816 citing authors

#	Article	IF	Citations
1	A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 10.e1-10.e6.	1.6	20
2	Neoadjuvant chemotherapy in highâ€risk soft tissue sarcomas: A Sarculatorâ€based risk stratification analysis of the ISGâ€STS 1001 randomized trial. Cancer, 2022, 128, 85-93.	4.1	46
3	The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer. European Urology Oncology, 2021, 4, 829-833.	5.4	20
4	Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. European Urology, 2020, 77, 636-643.	1.9	75
5	T2wâ€MRI signal normalization affects radiomics features reproducibility. Medical Physics, 2020, 47, 1680-1691.	3.0	82
6	First survival outcomes and additional secondary analyses from PURE-01: Pembrolizumab (pembro) before radical cystectomy (RC) in muscle-invasive urothelial bladder carcinoma (MIBC).. Journal of Clinical Oncology, 2019, 37, 391-391.	1.6	1
7	Towards the noninvasive identification of pathologic responders to neoadjuvant pembrolizumab in muscle-invasive urothelial bladder cancer (MIBC).. Journal of Clinical Oncology, 2019, 37, 4540-4540.	1.6	0
8	CÃ¡ncer de prÃ³stata, el problema del diagnÃ³stico Â¿Es la resonancia multiparamÃ©trica de prÃ³stata la soluciÃ³n?. Revista Chilena De Radiologia, 2019, 25, 60-66.	0.2	1
9	Texture analysis of T1â€w and T2â€w MR images allows a quantitative evaluation of radiationâ€induced changes of internal obturator muscles after radiotherapy for prostate cancer. Medical Physics, 2018, 45, 1518-1528.	3.0	7
10	Assessment of Stability and Discrimination Capacity of Radiomic Features on Apparent Diffusion Coefficient Images. Journal of Digital Imaging, 2018, 31, 879-894.	2.9	45
11	Radiomic analysis of soft tissues sarcomas can distinguish intermediate from highâ€grade lesions. Journal of Magnetic Resonance Imaging, 2018, 47, 829-840.	3.4	100
12	Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. Journal of Clinical Oncology, 2018, 36, 3353-3360.	1.6	474
13	Pre-implant magnetic resonance and transrectal ultrasound imaging in high-dose-rate prostate brachytherapy: comparison of prostate volumes, craniocaudal extents, and contours. Journal of Contemporary Brachytherapy, 2018, 10, 285-290.	0.9	3
14	Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study. Cancer, 2018, 124, 4056-4063.	4.1	40
15	Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 2018;74:294â€“306. European Urology, 2018, 74, e107-e108.	1.9	7
16	Interim results from PURE-01: A phase 2, open-label study of neoadjuvant pembrolizumab (pembro) before radical cystectomy for muscle-invasive urothelial bladder carcinoma (MIUC).. Journal of Clinical Oncology, 2018, 36, TPS533-TPS533.	1.6	4
17	PECULIAR: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (PEM) and epacadostat (EPA), preceding radical cystectomy (Cy), for patients (pts) with muscle-invasive urothelial bladder cancer (MIUBC).. Journal of Clinical Oncology, 2018, 36, TPS534-TPS534.	1.6	5
18	Short, full-dose neoadjuvant chemotherapy in localized high-risk adult soft tissue sarcomas (STS): An exploratory subgroup analysis on responding patients in a randomized controlled trial comparing 3 neoadjuvant versus 3 neoadjuvant + 2 adjuvant cycles of full dose anthracycline and ifosfamide chemotherapy at a 10yr median FU.. Journal of Clinical Oncology, 2018, 36, 11558-11558.	1.6	0

#	Article	IF	Citations
19	Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis. Cancer Journal (Sudbury, Mass), 2017, 23, 86-91.	2.0	71
20	Eleven-year Management of Prostate Cancer Patients on Active Surveillance: What have We Learned?. Tumori, 2017, 103, 464-474.	1.1	20
21	Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. Annals of Oncology, 2016, 27, 2283-2288.	1.2	90
22	Tumor response assessment by Choi criteria in localized high-risk soft tissue sarcoma (STS) treated with chemotherapy (CT): Update at 10-year follow-up of an exploratory analysis on a phase III trial.. Journal of Clinical Oncology, 2016, 34, 11044-11044.	1.6	1
23	Imatinib in advanced chordoma: A retrospective case series analysis. European Journal of Cancer, 2015, 51, 2609-2614.	2.8	78
24	Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies. Neuro-Oncology, 2014, 16, 72-80.	1.2	13
25	High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. Clinical Sarcoma Research, 2014, 4, 16.	2.3	44
26	Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. Clinical Sarcoma Research, 2013, 3, 8.	2.3	38
27	Phase II study on lapatinib in advanced EGFR-positive chordoma. Annals of Oncology, 2013, 24, 1931-1936.	1.2	122
28	Dacarbazine in Solitary Fibrous Tumor: A Case Series Analysis and Preclinical Evidence vis-Ã-vis Temozolomide and Antiangiogenics. Clinical Cancer Research, 2013, 19, 5192-5201.	7.0	67
29	Phase II Study of Imatinib in Advanced Chordoma. Journal of Clinical Oncology, 2012, 30, 914-920.	1.6	230
30	Sunitinib malate in solitary fibrous tumor (SFT). Annals of Oncology, 2012, 23, 3171-3179.	1.2	140
31	Tumor response assessment by modified Choi criteria in localized highâ€risk soft tissue sarcoma treated with chemotherapy. Cancer, 2012, 118, 5857-5866.	4.1	85
32	Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. Blood, 2011, 118, 4421-4430.	1.4	30
33	Sunitinib Malate and Figitumumab in Solitary Fibrous Tumor: Patterns and Molecular Bases of Tumor Response. Molecular Cancer Therapeutics, 2010, 9, 1286-1297.	4.1	83
34	Response to imatinib plus sirolimus in advanced chordoma. Annals of Oncology, 2009, 20, 1886-1894.	1.2	142
35	High-Grade Soft-Tissue Sarcomas: Tumor Response Assessmentâ€"Pilot Study to Assess the Correlation between Radiologic and Pathologic Response by Using RECIST and Choi Criteria. Radiology, 2009, 251, 447-456.	7.3	198
36	CEC enantioseparations of carboxylic acids on silicaâ€based monoliths modified with ergot alkaloid derivative. Electrophoresis, 2009, 30, 2890-2896.	2.4	7

#	Article	IF	Citations
37	Three successive pregnancies in a patient with chronic renal disease progressing from chronic renal dysfunction through to institution of dialysis during pregnancy and then on to maintenance dialysis. Nephrology Dialysis Transplantation, 2007, 22, 1236-1240.	0.7	8
38	Surgery of Residual Disease Following Molecular-targeted Therapy With Imatinib Mesylate in Advanced/Metastatic GIST. Annals of Surgery, 2007, 245, 341-346.	4.2	206
39	Impressive objective response in a patient with extensive metastatic melanoma including the brain. Melanoma Research, 2007, 17, 332-334.	1.2	1
40	CEC enantioseparations on chiral monolithic columns: A study of the stereoselective degradation of (R/S)-dichlorprop [2-(2,4-dichlorophenoxy)propionic acid] in soil. Electrophoresis, 2007, 28, 2613-2618.	2.4	24
41	Immobilized tyrosinase reactor for on-line HPLC applicationDevelopment and characterization. Sensors and Actuators B: Chemical, 2007, 121, 515-521.	7.8	22
42	Immobilization of mushroom tyrosinase on controlled pore glass: Effect of chemical modification. Sensors and Actuators B: Chemical, 2007, 125, 48-54.	7.8	17
43	Phenols removal by immobilized tyrosinase reactor in on-line high performance liquid chromatography. Analytica Chimica Acta, 2006, 580, 271-277.	5.4	36
44	Enantioseparation of 2-aryloxypropionic acids on chiral porous monolithic columns by capillary electrochromatography. Journal of Chromatography A, 2006, 1120, 69-74.	3.7	41
45	Vancomycin as chiral selector for enantioselective separation of selected profen nonsteroidal anti-inflammatory drugs incapillary liquid chromatography. Chirality, 2006, 18, 531-538.	2.6	24
46	Indirect resolution ofÃŸ-blocker agents by reversed-phase capillary electrochromatography. Electrophoresis, 2004, 25, 607-614.	2.4	14
47	Imatinib mesylate in chordoma. Cancer, 2004, 101, 2086-2097.	4.1	250
48	Chiral Separation of Pesticides by Coupledâ€Column Liquid Chromatography Application to the Stereoselective Degradation of Fenvalerate in Soil. Journal of Liquid Chromatography and Related Technologies, 2004, 27, 995-1012.	1.0	10
49	Inhibition of Polyphenol Oxidases Activity by Various Dipeptides. Journal of Agricultural and Food Chemistry, 2004, 52, 2741-2745.	5.2	45
50	Direct resolution of optically active isomers on chiral packings containing ergoline skeleton. 6. Enantioseparation of profens. , 1999, 11, 291-300.		21
51	Complex formation equilibria of some Î²-amino-alcohols with lead(II) and cadmium(II) in aqueous solution. Talanta, 1998, 47, 1077-1084.	5.5	13
52	Direct resolution of optically active isomers on chiral packings containing ergoline skeletons. Journal of Chromatography A, 1994, 666, 471-478.	3.7	29
53	Formation and dissociation equilibria of intermediate species in the oxidation of cobalt(II)-dipeptide complexes. Transition Metal Chemistry, 1991, 16, 296-300.	1.4	2
54	Separation of dansylamino acid enantiomers by thin-layer chromatography. Analyst, The, 1988, 113, 1245.	3.5	21

#	Article	IF	Citations
55	Solvent effects on complex formation: Cobalt(II)î—¸thiourea in ethyl acetate, propanol, propylene carbonate. Inorganica Chimica Acta, 1983, 75, 237-240.	2.4	4
56	Preparation and characterization of cobalt(III)bipyridine and phenanthroline complexes. Inorganica Chimica Acta, 1980, 44, L295-L297.	2.4	22